NCT Number: NCT01181505
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study
This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
About this study
After a single oral administration of 2 mg tolterodine in 31 healthy subjects (6 with the heterozygous mutation of HNF-4A G60D vs 25 subjects with wild type of that whose CYP2D6 genotype and gender were matched with variant group), blood were collected for 24hrs. Assay of tolterodine and the metabolite, 5-hyroxymethyl tolterodine was conducted using LC/MS/MS.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy subject whose HNF4a and CYP2D6 genotype ware determined
Exclusion criteria
- Subject whose HNF4a and CYP2D6 genotype ware not determined
Treatment and study plan
Primary outcomes
-
Cmax, AUC, CL, Vd, T1/2
Time frame: 24hr
Sponsors and collaborators
Lead sponsor
Inje University
Other
Registry information
Acronym: HNF4a
Important dates
- Study start
- 2007
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Aug 13, 2010
- Registry last updated
- Aug 13, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsAvocado and Postprandial Responses
NCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsHigh Image Matrix CT Reconstruction
NCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details